94 related articles for article (PubMed ID: 25462284)
1. Exploring binding affinity of oxaliplatin and carboplatin, to nucleoprotein structure of chromatin: spectroscopic study and histone proteins as a target.
Soori H; Rabbani-Chadegani A; Davoodi J
Eur J Med Chem; 2015 Jan; 89():844-50. PubMed ID: 25462284
[TBL] [Abstract][Full Text] [Related]
2. Investigation of the interaction between berberine and nucleosomes in solution: Spectroscopic and equilibrium dialysis approach.
Rabbani-Chadegani A; Mollaei H; Sargolzaei J
Spectrochim Acta A Mol Biomol Spectrosc; 2017 Feb; 173():418-424. PubMed ID: 27705846
[TBL] [Abstract][Full Text] [Related]
3. Spectroscopic detection of etoposide binding to chromatin components: the role of histone proteins.
Chamani E; Rabbani-Chadegani A; Zahraei Z
Spectrochim Acta A Mol Biomol Spectrosc; 2014 Dec; 133():292-9. PubMed ID: 24954753
[TBL] [Abstract][Full Text] [Related]
4. Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group.
Mandal R; Kalke R; Li XF
Chem Res Toxicol; 2004 Oct; 17(10):1391-7. PubMed ID: 15487901
[TBL] [Abstract][Full Text] [Related]
5. Spectroscopic studies of dactinomycin and vinorelbine binding to deoxyribonucleic acid and chromatin.
Rabbani-Chadegani A; Keyvani-Ghamsari S; Zarkar N
Spectrochim Acta A Mol Biomol Spectrosc; 2011 Dec; 84(1):62-7. PubMed ID: 21981942
[TBL] [Abstract][Full Text] [Related]
6. Binding of topotecan to chromatin: Insights into cooperative binding and comparison with DNA.
Babaei M; Rabbani-Chadegani A; Ghadam P
Int J Biol Macromol; 2015 Sep; 80():57-63. PubMed ID: 26092169
[TBL] [Abstract][Full Text] [Related]
7. Interaction of mitoxantrone, as an anticancer drug, with chromatin proteins, core histones and H1, in solution.
Hajihassan Z; Rabbani-Chadegani A
Int J Biol Macromol; 2011 Jan; 48(1):87-92. PubMed ID: 20943200
[TBL] [Abstract][Full Text] [Related]
8. Spectroscopic analysis of the interaction of valproic acid with histone H1 in solution and in chromatin structure.
Sargolzaei J; Rabbani-Chadegani A; Mollaei H; Deezagi A
Int J Biol Macromol; 2017 Jun; 99():427-432. PubMed ID: 28263810
[TBL] [Abstract][Full Text] [Related]
9. The X-ray structure of the complex formed in the reaction between oxaliplatin and lysozyme.
Messori L; Marzo T; Merlino A
Chem Commun (Camb); 2014 Aug; 50(61):8360-2. PubMed ID: 24943911
[TBL] [Abstract][Full Text] [Related]
10. Glutathione modified CdTe quantum dots as a label for studying DNA interactions with platinum based cytostatics.
Ryvolova M; Smerkova K; Chomoucka J; Hubalek J; Adam V; Kizek R
Electrophoresis; 2013 Mar; 34(6):801-8. PubMed ID: 23400813
[TBL] [Abstract][Full Text] [Related]
11. A comparison study on RNase A oligomerization induced by cisplatin, carboplatin and oxaliplatin.
Picone D; Donnarumma F; Ferraro G; Gotte G; Fagagnini A; Butera G; Donadelli M; Merlino A
J Inorg Biochem; 2017 Aug; 173():105-112. PubMed ID: 28511060
[TBL] [Abstract][Full Text] [Related]
12. Investigation on the chromium oxide interaction with soluble chromatin and histone H1: a spectroscopic study.
Khorsandi K; Rabbani-Chadegani A
Int J Biol Macromol; 2014 Sep; 70():57-63. PubMed ID: 24960121
[TBL] [Abstract][Full Text] [Related]
13. The effect of vinca alkaloid anticancer drug, vinorelbine, on chromatin and histone proteins in solution.
Rabbani-Chadegani A; Chamani E; Hajihassan Z
Eur J Pharmacol; 2009 Jun; 613(1-3):34-8. PubMed ID: 19394329
[TBL] [Abstract][Full Text] [Related]
14. ESI mass spectrometry and X-ray diffraction studies of adducts between anticancer platinum drugs and hen egg white lysozyme.
Casini A; Mastrobuoni G; Temperini C; Gabbiani C; Francese S; Moneti G; Supuran CT; Scozzafava A; Messori L
Chem Commun (Camb); 2007 Jan; (2):156-8. PubMed ID: 17180231
[TBL] [Abstract][Full Text] [Related]
15. Structural and functional evaluation of interaction between mammalian ribosomal RNA with platinum-containing antineoplastic drugs.
Theile D; Kos M
Toxicol Lett; 2016 Feb; 242():47-52. PubMed ID: 26656794
[TBL] [Abstract][Full Text] [Related]
16. Studies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins.
Hajihassan Z; Rabbani-Chadegani A
J Biomed Sci; 2009 Mar; 16(1):31. PubMed ID: 19284573
[TBL] [Abstract][Full Text] [Related]
17. Analysis of cytotoxicities of platinum compounds.
Goodisman J; Hagrman D; Tacka KA; Souid AK
Cancer Chemother Pharmacol; 2006 Jan; 57(2):257-67. PubMed ID: 16028101
[TBL] [Abstract][Full Text] [Related]
18. TCEP-based rSDS-PAGE AND nLC-ESI-LTQ-MS/MS for oxaliplatin metalloproteomic analysis.
Mena ML; Moreno-Gordaliza E; Gómez-Gómez MM
Talanta; 2013 Nov; 116():581-92. PubMed ID: 24148449
[TBL] [Abstract][Full Text] [Related]
19. Kinetic study on the reactions of platinum drugs with glutathione.
Hagrman D; Goodisman J; Souid AK
J Pharmacol Exp Ther; 2004 Feb; 308(2):658-66. PubMed ID: 14610218
[TBL] [Abstract][Full Text] [Related]
20. Experimental study of renal disorder caused by oxaliplatin in rat renal cortical slices.
Kanou T; Uozumi J; Soejima K; Tokuda Y; Masaki Z
Clin Exp Nephrol; 2004 Dec; 8(4):310-5. PubMed ID: 15619029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
